Exicure Inc
XCUR
NASDAQ
Biotechnology
$1.25
USD
-0.06 (-4.58%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $8.29M
Volume 21.8K
About Exicure Inc
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The company is headquartered in Chicago, Illinois and currently employs 8 full-time employees. The company went IPO on 2018-05-09. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The firm is also exploring strategic alternatives to maximize stockholder value.
CEO
Mr. Jung Soo Kim
HQ
Chicago, ILLINOIS, US
Founded
2018
Employees
8
Key Metrics
2 metrics our research team weighs before forming a view on XCUR.
Based on Quantli research · SEC filings · as of Q1 2026
METRIC
VALUE
CHANGE
TREND (3Y)
ROE (TTM)
-466.3%
-414.8 pp
Free Cash Flow (TTM)
$-8.10M
—
Financial Snapshot
Revenue
$0
— YoY
Gross Margin
—
— YoY
Net Income
$-9.78M
-66.9%
YoY
Operating Cash Flow
$-8.10M
-99.6%
YoY
Key Statistics
Open
$1.33
Previous Close
$1.31
Day Range
$1.25 - $1.33
52 Week Range
$1.18 - $9.48
Volume
21.8K
Average Volume (10 Days)
40.0K
Dividend Yield
—
Valuation Measurement
Market Cap
$8.29M
P/E Ratio (TTM)
—
Price / Book
3.95
Financial Highlights
Return on Assets
-76.7%
Return on Equity
-466.3%
Revenue (TTM)
$0
Net Income (TTM)
$-9.78M
Diluted EPS (TTM)
-$1.55
Total Cash (MRQ)
$2.60M
Levered FCF (TTM)
$-8.10M
Turn research into action
Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.
Earnings Calendar
Next Earnings
Estimated Q3 Release
Nov 05